Boyd E J, Wormsley K G
Eur J Clin Pharmacol. 1984;26(4):443-7. doi: 10.1007/BF00542138.
The gastric inhibitory effects of loxtidine, a new histamine H2-receptor antagonist, were studied in healthy volunteers. Doses of 20, 40 and 80 mg given in the evening reduced nocturnal acid secretion by 91, 97 and 95%, respectively, and nocturnal pepsin secretion by 86, 89 and 90%, respectively. The same doses also increased median 24-hour intragastric pH from 1.6 to 4.1, 5.4 and 5.5, respectively, but intragastric pH had returned to control values by the end of the 24-hour study period. Loxtidine at a dose of 40 mg twice daily rendered gastric contents virtually anacid throughout the 24-hour study period. The powerful gastric inhibitory effects of loxtidine denote a potential use in the treatment of peptic diseases.
在健康志愿者中研究了新型组胺H2受体拮抗剂洛替丁的胃抑制作用。晚上给予20、40和80毫克剂量分别使夜间胃酸分泌减少91%、97%和95%，夜间胃蛋白酶分泌分别减少86%、89%和90%。相同剂量还使24小时胃内pH中位数分别从1.6升至4.1、5.4和5.5，但在24小时研究期结束时胃内pH已恢复至对照值。每日两次服用40毫克剂量的洛替丁在整个24小时研究期内使胃内容物几乎无酸。洛替丁强大的胃抑制作用表明其在治疗消化性疾病方面具有潜在用途。
